RAC 0.57% $1.75 race oncology ltd

Ann: Race Strategic Update August 2023, page-288

  1. 19,023 Posts.
    lightbulb Created with Sketch. 5823
    It is a shame so many people have forgotten all the clinical results that have been released. The 40% response rate in Sheba 1 and the 50% bridge to transplant in the first stage of Sheba 2 trial. Oh and the 47 trials done by Lederle in 1800 patients including the Phase 3 breast cancer trial. Bisantrene is not a drug lacking clinical evidence of efficacy.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.